Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bergui

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Cerebellum (London, England)|April 5, 2013
Intrinsic connectivity networks within cerebellum and beyond in eating disordersF Amianto, F D'Agata, L Lavagnino, et al.
Neuroradiology|September 1, 2006
Functional MR study of a motor task and the tower of London task at 1.0 TA Boghi, O Rampado, M Bergui, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 18, 2001
Interferon-beta dose and efficacy: the OPTIMS studyL Durelli, A Oggero, E Verdun, et al.
Neurology|July 1, 1996
Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatmentL Durelli, M R Bongioanni, B Ferrero, et al.
Journal of Neurology|September 1, 1995
Propofol analgesia in central pain: preliminary clinical observationsS Canavero, V Bonicalzi, C A Pagni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 8, 2006
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with NabP Barbero, M Bergui, E Versino, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 1, 1996
Long term recombinant interferon alpha treatment in MS with special emphasis to side effectsL Durelli, M R Bongioanni, B Ferrero, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 8, 2007
MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosisL Durelli, P Barbero, M Bergui, et al.
Expert Opinion on Biological Therapy|March 13, 2009
Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1bL Durelli, P Barbero, A Cucci, et al.
Neuroimage|September 29, 2006
The effect of gender on planning: An fMRI study using the Tower of London taskA Boghi, R Rasetti, F Avidano, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Cerebellum (London, England)|April 5, 2013
Intrinsic connectivity networks within cerebellum and beyond in eating disordersF Amianto, F D'Agata, L Lavagnino, et al.
Neuroradiology|September 1, 2006
Functional MR study of a motor task and the tower of London task at 1.0 TA Boghi, O Rampado, M Bergui, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 18, 2001
Interferon-beta dose and efficacy: the OPTIMS studyL Durelli, A Oggero, E Verdun, et al.
Neurology|July 1, 1996
Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatmentL Durelli, M R Bongioanni, B Ferrero, et al.
Journal of Neurology|September 1, 1995
Propofol analgesia in central pain: preliminary clinical observationsS Canavero, V Bonicalzi, C A Pagni, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 8, 2006
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with NabP Barbero, M Bergui, E Versino, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 1, 1996
Long term recombinant interferon alpha treatment in MS with special emphasis to side effectsL Durelli, M R Bongioanni, B Ferrero, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 8, 2007
MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosisL Durelli, P Barbero, M Bergui, et al.
Expert Opinion on Biological Therapy|March 13, 2009
Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1bL Durelli, P Barbero, A Cucci, et al.
Neuroimage|September 29, 2006
The effect of gender on planning: An fMRI study using the Tower of London taskA Boghi, R Rasetti, F Avidano, et al.
Pageof 6